Comprehensive Research Report: FGF7 (Fibroblast Growth Factor 7) - Gene and Functional Annotation Falcon Edison Scientific Literature 34 citations 1 artifacts 2026-09-30T06:02:10.156537

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: FGF7 (Fibroblast Growth Factor 7) - Gene and Functional Annotation

Gene Identity and Protein Characteristics

FGF7 (fibroblast growth factor 7), also known as keratinocyte growth factor (KGF), is a member of the fibroblast growth factor family encoded by the human FGF7 gene located on chromosome 15q15–21.1 (edirisinghe2024decodingfgffgfrsignaling pages 5-7). The mature protein consists of 194 amino acid residues and belongs to the FGF7 subfamily, which also includes FGF3, FGF10, and FGF22 (edirisinghe2024decodingfgffgfrsignaling pages 5-7). Structurally, FGF7 adopts the characteristic FGF β-trefoil fold, with only 10 of 12 β-strands arranged antiparallelly in an ordered manner, although the overall trifold symmetry is retained (edirisinghe2024decodingfgffgfrsignaling pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 7-8). The protein contains conserved cysteine residues (Cys17 and Cys83) that do not form a disulfide bond, and a heparin-binding domain involving residues Arg18, Asn92, Asn114, Gln115, Val120, Lys124, Gln129, Lys130, and Thr131 (edirisinghe2024decodingfgffgfrsignaling pages 5-7). This structural organization confirms that the gene being researched matches the UniProt entry P21781.

Primary Function: Paracrine Signaling Growth Factor

FGF7 functions as a paracrine signaling molecule rather than an enzyme or transporter. Its primary role is to mediate mesenchymal-to-epithelial communication that promotes epithelial cell proliferation, survival, differentiation, barrier maintenance, and morphogenesis (edirisinghe2024decodingfgffgfrsignaling pages 7-8, edirisinghe2024decodingfgffgfrsignaling pages 5-7). Unlike enzymes that catalyze chemical reactions, FGF7 acts as a ligand that activates cell-surface receptors to initiate intracellular signaling cascades.

Receptor Specificity and Binding Mechanism

FGF7 exhibits high specificity for the epithelial splice isoform FGFR2b (also designated FGFR2-IIIb), which is the "b" variant of fibroblast growth factor receptor 2 (ferguson2021fibroblastgrowthfactor pages 2-3, edirisinghe2024decodingfgffgfrsignaling pages 7-8, edirisinghe2024decodingfgffgfrsignaling pages 5-7). This receptor specificity is critical to FGF7's function: epithelial cells express FGFR2b, while mesenchymal cells typically express the alternative FGFR2c isoform (farooq2021theroleof pages 2-5). The FGF7-FGFR2b interaction requires heparan sulfate (HS) as an essential cofactor that stabilizes the signaling complex and promotes receptor dimerization and activation (edirisinghe2024decodingfgffgfrsignaling pages 5-7). Specific residues Val103 and Leu142 in FGF7 are important for the FGFR2b interaction (edirisinghe2024decodingfgffgfrsignaling pages 7-8). The ligand-binding specificity arises from contacts between FGF7 and the D2 and alternatively spliced D3 domains of FGFR2b (edirisinghe2024decodingfgffgfrsignaling pages 5-7).

Cellular Localization and Expression Pattern

FGF7 operates through a paracrine signaling mechanism, with distinct producer and responder cell populations. FGF7 is produced and secreted by mesenchymal or stromal cells, particularly fibroblasts and dermal papilla cells (ferguson2021fibroblastgrowthfactor pages 8-9, edirisinghe2024decodingfgffgfrsignaling pages 5-7). In pathological contexts, cancer-associated fibroblasts (CAFs) represent an important source of FGF7 in the tumor microenvironment (edirisinghe2024decodingfgffgfrsignaling pages 7-8, edirisinghe2025pathologyandtherapeutic pages 8-10).

The responding cells are those that express FGFR2b, primarily epithelial cell populations including keratinocytes, alveolar type II cells, intestinal epithelial cells, and various epithelial progenitor populations (edirisinghe2024decodingfgffgfrsignaling pages 5-7, ferrarese2026anfgf7fgfr2klf4feedback pages 1-5). This mesenchymal-to-epithelial signaling arrangement is fundamental to FGF7's biological function in coordinating tissue architecture and repair.

Downstream Signaling Pathways

Upon FGF7 binding, FGFR2b undergoes ligand-induced dimerization and trans-autophosphorylation of intracellular tyrosine residues, creating docking sites for downstream signaling adaptors (ferguson2021fibroblastgrowthfactor pages 5-7, ferguson2021fibroblastgrowthfactor pages 2-3). FGF7-FGFR2b signaling activates four major intracellular pathways:

1. RAS-RAF-MEK-ERK/MAPK Pathway

The phosphorylated receptor recruits FRS2α, which associates with GRB2 and the guanine nucleotide exchange factor SOS, leading to RAS activation and subsequent RAF-MEK-ERK/MAPK signaling (liu2026fgffamilyin pages 3-4, ferguson2021fibroblastgrowthfactor pages 3-5, edirisinghe2024decodingfgffgfrsignaling pages 1-3). This pathway regulates cell proliferation, differentiation, and transcriptional responses through activation of Ets-family transcription factors (edirisinghe2024decodingfgffgfrsignaling pages 1-3). FGF7-FGFR2b signaling has been shown to produce transient ERK1/2 activation due to CBL-mediated receptor ubiquitination and degradation (ferguson2021fibroblastgrowthfactor pages 5-7).

2. PI3K-AKT-mTOR Pathway

FRS2α-associated GAB1 recruits and activates PI3K, which generates PIP3 and activates AKT (liu2026fgffamilyin pages 3-4, ferguson2021fibroblastgrowthfactor pages 3-5). Activated AKT promotes cell survival by inhibiting pro-apoptotic proteins (Caspase 9, BAD, BAX) and can signal to mTORC1 to support growth and metabolism (liu2026fgffamilyin pages 3-4, edirisinghe2024decodingfgffgfrsignaling pages 1-3). This pathway is particularly important for FGF7's cytoprotective and survival-promoting effects.

3. PLCγ Pathway

Direct recruitment of phospholipase C gamma (PLCγ) to phosphorylated FGFR2b tyrosine residues leads to hydrolysis of PIP2 into IP3 and DAG (liu2026fgffamilyin pages 3-4, ferguson2021fibroblastgrowthfactor pages 3-5). IP3 promotes intracellular calcium release and NFAT nuclear translocation, while DAG activates protein kinase C (PKC) and downstream substrates including MARCKS (liu2026fgffamilyin pages 3-4).

4. STAT Pathway

FGFR activation can also phosphorylate and activate STAT1, STAT3, and STAT5 transcription factors, which translocate to the nucleus to regulate gene expression (edirisinghe2024decodingfgffgfrsignaling pages 1-3).

5. Novel FGF7-FGFR2-KLF4 Anti-inflammatory Feedback Loop

Recent research (2026) has identified a novel FGF7-FGFR2b-MEK/ERK-KLF4 signaling axis that sustains anti-inflammatory responses in epithelial cells (ferrarese2026anfgf7fgfr2klf4feedback pages 1-5, ferrarese2026anfgf7fgfr2klf4feedback pages 9-12, ferrarese2026anfgf7fgfr2klf4feedback pages 5-7). FGF7 activates FGFR2b and downstream MEK-ERK signaling, which modulates the transcription factor KLF4's activity and protein interactome (ferrarese2026anfgf7fgfr2klf4feedback pages 7-9, ferrarese2026anfgf7fgfr2klf4feedback pages 9-12). KLF4 suppresses pro-inflammatory genes including IL6 and interferon-stimulated genes, while simultaneously promoting expression of FGFR2 and the signaling adaptor FRS2α, creating a positive feedback loop that maintains anti-inflammatory signaling (ferrarese2026anfgf7fgfr2klf4feedback pages 9-12, ferrarese2026anfgf7fgfr2klf4feedback pages 40-44). This pathway was demonstrated in human keratinocytes and in a mouse psoriasiform inflammation model, where FGF7 reduced expression of inflammatory genes such as Il6, Rsad2, and Ifnl3 (ferrarese2026anfgf7fgfr2klf4feedback pages 7-9, ferrarese2026anfgf7fgfr2klf4feedback pages 5-7).

Biological Functions

Development and Organ Morphogenesis

FGF7 plays essential roles in multiple organ-development programs. In lung development, FGF7 acts as one of the master regulators coordinating initial tissue morphogenesis, epithelial branching, and alveolar type II cell differentiation (edirisinghe2024decodingfgffgfrsignaling pages 7-8, liu2026fgffamilyin pages 11-12, liu2026fgffamilyin pages 6-8). It promotes self-renewal of alveolar type II cells and supports alveolar expansion, and can induce embryonic lung epithelial cells to form alveolus-like organoids in culture (liu2026fgffamilyin pages 11-12). However, Fgf7 knockout mice have normal lung histology, indicating functional redundancy with other FGFs (liu2026fgffamilyin pages 11-12).

In kidney development, FGF7 promotes ureteric bud outgrowth and branching, supports collecting duct maturation, and contributes to nephron formation (liu2026fgffamilyin pages 12-13). Loss of Fgf7 reduces ureteric bud branching and collecting duct maturation with secondary nephron loss, while exogenous FGF7 enhances ureteric bud outgrowth and increases nephron numbers in culture (liu2026fgffamilyin pages 12-13).

FGF7 also participates in mammary gland morphogenesis through an FGF7-TGFα-MAPK-ERK1/2 pathway, promotes osteogenic differentiation through the ERK-Runx2 pathway in embryonic and mesenchymal stem cells, supports pancreatic progenitor development via MAPK signaling, contributes to submandibular gland branching morphogenesis, and is involved in cartilage, limb, endometrial, and tooth development (edirisinghe2024decodingfgffgfrsignaling pages 7-8).

Tissue Repair and Wound Healing

FGF7 is a critical factor in epithelial tissue repair across multiple organ systems. In intestinal injury, FGF7 promotes healing by stimulating epithelial proliferation, increasing mucus production, reducing inflammation, and protecting epithelial integrity (chen2022rolesofthe pages 8-10). It limits epithelial apoptosis and tight-junction disruption during ischemia/reperfusion and radiation injury through an AhR-E2F1-FGFR2IIIb signaling pathway (chen2022rolesofthe pages 8-10). In the kidney, FGF7 contributes to tubular cell growth and repair after damage (chen2022rolesofthe pages 8-10). Deficient FGF7 delays cutaneous wound healing in diabetic animals (chen2022rolesofthe pages 8-10).

The wound-healing functions of FGF7 include promoting re-epithelialization, supporting cellular proliferation and migration, enhancing antibacterial activity, improving fibroblast contraction and wound contraction, and supporting improved scar formation (chen2022rolesofthe pages 10-11).

Hair Follicle Development and Growth

FGF7 plays important regulatory roles in hair follicle biology. It is expressed in dermal papilla cells and hair follicle mesenchyme, with peak expression during growth stage V (wang2025recentadvancesin pages 6-8, wang2025recentadvancesin pages 8-10). FGF7 binds FGFR2 on hair follicle stromal cells and stimulates their proliferation, helping to initiate the hair follicle growth (anagen) phase (wang2025recentadvancesin pages 6-8). Functional effects include prolonging the growth period, promoting proliferation of the hair embryo, activating hair follicle stem cells, and enhancing hair shaft growth and elongation (wang2025recentadvancesin pages 6-8, wang2025recentadvancesin pages 8-10, wang2025recentadvancesin pages 17-18). FGF7 also improves hair follicle survival after chemotherapy or other cytotoxic injuries (wang2025recentadvancesin pages 8-10, wang2025recentadvancesin pages 17-18).

However, FGF7 has context-dependent effects in androgenetic alopecia: dihydrotestosterone (DHT) stimulates FGF7 secretion from dermal papilla cells, which then inhibits Wnt signaling in hair progenitor cells, contributing to impaired follicular growth in susceptible individuals (wang2025recentadvancesin pages 15-17).

Clinical Applications

Palifermin for Oral Mucositis

The most established clinical application of FGF7 is palifermin (recombinant keratinocyte growth factor-1, marketed as Kepivance), a truncated recombinant form of human FGF7 that was approved by the U.S. FDA in 2004 (chen2022rolesofthe pages 10-11, chen2022rolesofthe pages 11-12). Palifermin is used for the prevention and treatment of severe oral mucositis in cancer patients undergoing chemotherapy and radiotherapy, particularly in the context of hematopoietic malignancy therapy (ferrarese2026anfgf7fgfr2klf4feedback pages 1-5, chen2022rolesofthe pages 10-11, chen2022rolesofthe pages 8-10). The clinical dose is 60 μg/kg/day (chen2022rolesofthe pages 11-12). Reported adverse effects include skin and oral toxicities (chen2022rolesofthe pages 11-12).

Investigational Clinical Applications

Palifermin has been evaluated in clinical trials for several additional indications, including:
- Dysphagia associated with non-small-cell lung cancer (Phase 2 trial) (edirisinghe2025pathologyandtherapeutic pages 23-24)
- Prevention of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell transplantation (Phase 1/2 trial), where it was reported to be safe and did not significantly affect engraftment (edirisinghe2025pathologyandtherapeutic pages 23-24, edirisinghe2025pathologyandtherapeutic pages 38-40)
- Oral mucositis in acute lymphoblastic leukemia and metastatic colorectal cancer (edirisinghe2025pathologyandtherapeutic pages 30-31)
- Head and neck squamous cell carcinoma with concurrent chemoradiation (Phase 2 study) (edirisinghe2025pathologyandtherapeutic pages 30-31)

Preclinical studies have demonstrated potential applications in diabetic wound healing, islet transplantation, bone regeneration, and liver injury, though these remain experimental (edirisinghe2025pathologyandtherapeutic pages 30-31).

Disease Associations and Pathological Roles

Cancer and Tumor Microenvironment

FGF7 can become pathogenic when stromal or tumor signaling is dysregulated. Cancer-associated fibroblasts produce FGF7, which acts on FGFR2b-expressing epithelial tumor cells to promote cancer progression (edirisinghe2024decodingfgffgfrsignaling pages 7-8, edirisinghe2024decodingfgffgfrsignaling pages 25-27). In ovarian cancer, CAF-derived FGF7 is associated with greater metastatic potential and poorer prognosis, potentially through FGF7-FGFR2b-mediated inhibition of hypoxia-inducible factor 1α degradation (edirisinghe2024decodingfgffgfrsignaling pages 7-8).

In gastric cancer, FGF7 binding to FGFR2 activates the PI3K-AKT-mTOR pathway and increases expression of thrombospondin 1 (THBS1), promoting cancer cell migration, invasion, tumor growth, and metastasis (ferguson2021fibroblastgrowthfactor pages 8-9, edirisinghe2024decodingfgffgfrsignaling pages 7-8). Knockdown of thrombospondin 1 inhibited FGF7-induced gastric cancer progression (edirisinghe2024decodingfgffgfrsignaling pages 7-8).

FGF7 overexpression has also been associated with proliferation, angiogenesis, and epithelial-to-mesenchymal transition in breast cancer; proliferation in ameloblastoma; invasion in retinoblastoma; progression and drug resistance in cholangiocarcinoma; and disease progression in urothelial carcinoma and leukemia/myeloblastoma (edirisinghe2024decodingfgffgfrsignaling pages 7-8, edirisinghe2024decodingfgffgfrsignaling pages 25-27).

Inflammation

FGF7 exhibits context-dependent immunomodulatory effects. Recent evidence demonstrates that FGF7 can suppress IL6 and interferon-associated epithelial inflammation through the FGFR2b-MEK/ERK-KLF4 mechanism, broadly suppressing inflammatory transcriptional programs induced by poly(I:C), TNFα, and other stimuli (ferrarese2026anfgf7fgfr2klf4feedback pages 1-5, ferrarese2026anfgf7fgfr2klf4feedback pages 9-12, ferrarese2026anfgf7fgfr2klf4feedback pages 5-7). However, one study reported that FGF7 promotes TNF-α expression in immortalized human keratinocytes via the FGFR2-AKT-NF-κB signaling axis (farooq2021theroleof pages 11-12), indicating that anti-inflammatory activity should be considered tissue-, stimulus-, and timing-dependent rather than universal.

Recent Developments (2023-2026)

Several significant advances in FGF7 research have been published in recent years:

  1. FGF7-FGFR2-KLF4 Anti-inflammatory Feedback Loop (2026): Ferrarese et al. discovered a novel feedback circuit in which FGF7 activates FGFR2b-MEK/ERK signaling, modulates KLF4 activity to suppress pro-inflammatory genes, while KLF4 simultaneously promotes expression of FGFR2 and FRS2α to sustain the pathway (ferrarese2026anfgf7fgfr2klf4feedback pages 1-5, ferrarese2026anfgf7fgfr2klf4feedback pages 9-12).

  2. Comprehensive FGF Family Reviews (2024-2026): Multiple authoritative reviews have synthesized current understanding of FGF biology, including detailed mechanistic insights into FGF7 structure, signaling, and disease relevance (edirisinghe2024decodingfgffgfrsignaling pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 7-8, liu2026fgffamilyin pages 12-13).

  3. Hair Follicle Growth Mechanisms (2025): Wang et al. provided updated understanding of FGF7's roles in hair follicle stem cell activation, growth phase regulation, and potential therapeutic applications for androgenetic alopecia (wang2025recentadvancesin pages 6-8, wang2025recentadvancesin pages 8-10, wang2025recentadvancesin pages 17-18).

  4. Pathology and Therapeutic Significance (2025): Edirisinghe et al. reviewed differential expression and regulation of FGF7 under physiological and pathological conditions, including therapeutic interventions (edirisinghe2025pathologyandtherapeutic pages 28-30).

Summary

Category Details Citations
Gene and protein identity Human FGF7 encodes fibroblast growth factor 7, also called keratinocyte growth factor (KGF). It maps to chromosome 15q15–21.1 and is synthesized as a 194-amino-acid precursor with the characteristic FGF β-trefoil fold and heparin-binding region. (edirisinghe2024decodingfgffgfrsignaling pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 7-8)
Receptor specificity FGF7 is a high-specificity ligand for the epithelial splice isoform FGFR2b (FGFR2-IIIb). Cell-surface or extracellular-matrix heparan sulfate acts as a cofactor that stabilizes the signaling complex and promotes receptor dimerization and activation. (ferguson2021fibroblastgrowthfactor pages 2-3, edirisinghe2024decodingfgffgfrsignaling pages 7-8, edirisinghe2024decodingfgffgfrsignaling pages 5-7)
Expression and localization FGF7 is a classically secreted, extracellular paracrine signal produced mainly by mesenchymal or stromal cells, especially fibroblasts. It acts locally on neighboring FGFR2b-positive epithelial cells, including keratinocytes; heparan sulfate helps retain and present it in the pericellular extracellular environment. (ferguson2021fibroblastgrowthfactor pages 8-9, edirisinghe2024decodingfgffgfrsignaling pages 5-7, edirisinghe2024decodingfgffgfrsignaling pages 25-27)
Signaling pathways Ligand binding activates FGFR2b dimerization and tyrosine autophosphorylation. Major downstream branches are FRS2–GRB2–SOS–RAS–RAF–MEK–ERK/MAPK, FRS2–GAB1–PI3K–AKT–mTOR, PLCγ–IP3/DAG–Ca²⁺/PKC, and context-dependent STAT signaling. Emerging preprint evidence proposes an epithelial FGFR2b–MEK/ERK–KLF4 anti-inflammatory feedback circuit. (ferguson2021fibroblastgrowthfactor pages 5-7, ferguson2021fibroblastgrowthfactor pages 2-3, edirisinghe2024decodingfgffgfrsignaling pages 1-3, ferrarese2026anfgf7fgfr2klf4feedback pages 9-12)
Primary functions FGF7 is not an enzyme or transporter; it is a receptor-activating growth factor. Its central function is mesenchymal-to-epithelial communication that promotes epithelial-cell proliferation, survival, differentiation, barrier maintenance, and morphogenesis. Documented roles span skin and mucosal repair, alveolar epithelial growth, gland branching, pancreatic development, osteogenesis, and other organ-development programs. (edirisinghe2024decodingfgffgfrsignaling pages 7-8, chen2022rolesofthe pages 8-10)
Tissue repair and wound healing FGF7 supports re-epithelialization and barrier restoration, limits epithelial apoptosis and tight-junction damage, and can increase mucus production while reducing injury-associated inflammation. Experimental evidence implicates it in repair of skin, intestine, kidney tubules, and other epithelial tissues. (chen2022rolesofthe pages 8-10, chen2022rolesofthe pages 10-11)
Clinical application Palifermin is a truncated recombinant human FGF7 marketed as Kepivance. Its established application is prevention or treatment of severe therapy-associated oral mucositis in selected cancer-treatment settings; a cited clinical regimen is 60 μg/kg/day. Other epithelial-injury, transplantation, and wound-repair indications remain investigational or context dependent. (chen2022rolesofthe pages 10-11, edirisinghe2025pathologyandtherapeutic pages 23-24, chen2022rolesofthe pages 11-12)
Cancer and tumor microenvironment FGF7 can become pathogenic when stromal or tumor signaling is dysregulated. Cancer-associated fibroblast-derived FGF7 and tumor-cell FGFR2b signaling have been associated with proliferation, invasion, angiogenesis, metastasis, and drug resistance. One defined mechanism in gastric cancer is FGFR2–PI3K/AKT/mTOR–THBS1 signaling. (edirisinghe2024decodingfgffgfrsignaling pages 7-8, ferguson2021fibroblastgrowthfactor pages 8-9, edirisinghe2024decodingfgffgfrsignaling pages 25-27)
Inflammation FGF7 has context-dependent immunomodulatory effects. Emerging evidence indicates that it can suppress IL6 and interferon-associated epithelial transcription through an FGFR2b–MEK/ERK–KLF4 mechanism, but earlier keratinocyte work reported induction of TNF-α through FGFR2–AKT–NF-κB. Anti-inflammatory activity should therefore be treated as tissue-, stimulus-, and timing-dependent rather than universal. (ferrarese2026anfgf7fgfr2klf4feedback pages 7-9, ferrarese2026anfgf7fgfr2klf4feedback pages 9-12, ferrarese2026anfgf7fgfr2klf4feedback pages 5-7, farooq2021theroleof pages 11-12)

Table: This table consolidates the identity, extracellular localization, receptor specificity, signaling mechanism, physiological functions, clinical implementation, and disease relevance of human FGF7. It distinguishes established biology and clinical use from emerging or context-dependent findings.

FGF7 is a paracrine signaling growth factor that mediates critical mesenchymal-to-epithelial communication through specific binding to FGFR2b with heparan sulfate as a cofactor. Produced by mesenchymal cells and acting on epithelial cells, FGF7 activates multiple downstream pathways including MAPK, PI3K-AKT, PLCγ, STAT, and the recently discovered FGFR2-KLF4 anti-inflammatory feedback loop. Its primary biological functions encompass epithelial proliferation and survival, organ development (lung, kidney, mammary gland, bone), tissue repair and wound healing, and hair follicle growth regulation. The recombinant form palifermin is clinically approved for prevention of chemotherapy-induced oral mucositis. In pathological contexts, dysregulated FGF7 signaling, particularly from cancer-associated fibroblasts, can promote tumor progression, invasion, and metastasis. Recent research (2023-2026) has revealed new mechanistic insights into FGF7's anti-inflammatory functions and expanded understanding of its roles in development, regeneration, and disease.


Key References:
- Edirisinghe et al., 2024. "Decoding FGF/FGFR Signaling" - Biomolecules 14:1622
- Ferrarese et al., 2026. "An FGF7-FGFR2-KLF4 feedback loop" - bioRxiv
- Liu et al., 2026. "FGF family in health and disease" - Molecular Biomedicine 7(1)
- Wang et al., 2025. "Recent Advances in FGF in Hair Follicle Growth" - Biomolecules 15:1198
- Chen et al., 2022. "Roles of FGF signal transduction in tissue injury repair" - Burns & Trauma
- Farooq et al., 2021. "Role of FGF Signaling in Tissue Repair" - Cells 10:3242

References

  1. (edirisinghe2024decodingfgffgfrsignaling pages 5-7): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

  2. (edirisinghe2024decodingfgffgfrsignaling pages 7-8): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

  3. (ferguson2021fibroblastgrowthfactor pages 2-3): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

  4. (farooq2021theroleof pages 2-5): Mariya Farooq, Abdul Waheed Khan, Moon Suk Kim, and Sangdun Choi. The role of fibroblast growth factor (fgf) signaling in tissue repair and regeneration. Cells, 10:3242, Nov 2021. URL: https://doi.org/10.3390/cells10113242, doi:10.3390/cells10113242. This article has 446 citations.

  5. (ferguson2021fibroblastgrowthfactor pages 8-9): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

  6. (edirisinghe2025pathologyandtherapeutic pages 8-10): Oshadi Edirisinghe, Gaëtane Ternier, and Thallapuranam Krishnaswamy Suresh Kumar. Pathology and therapeutic significance of fibroblast growth factors. Targets, 3:5, Feb 2025. URL: https://doi.org/10.3390/targets3010005, doi:10.3390/targets3010005. This article has 6 citations.

  7. (ferrarese2026anfgf7fgfr2klf4feedback pages 1-5): Luca Ferrarese, Daria Wüst, Liliana Bento Lopes, Ismail Küçükaylak, Sibilla Sander, Joanne Gerber, Jörn Dengjel, and Sabine Werner. An fgf7-fgfr2-klf4 feedback loop sustains anti-inflammatory signaling in epithelial cells. bioRxiv, Mar 2026. URL: https://doi.org/10.64898/2026.03.20.711763, doi:10.64898/2026.03.20.711763. This article has 0 citations.

  8. (ferguson2021fibroblastgrowthfactor pages 5-7): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

  9. (liu2026fgffamilyin pages 3-4): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

  10. (ferguson2021fibroblastgrowthfactor pages 3-5): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

  11. (edirisinghe2024decodingfgffgfrsignaling pages 1-3): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

  12. (ferrarese2026anfgf7fgfr2klf4feedback pages 9-12): Luca Ferrarese, Daria Wüst, Liliana Bento Lopes, Ismail Küçükaylak, Sibilla Sander, Joanne Gerber, Jörn Dengjel, and Sabine Werner. An fgf7-fgfr2-klf4 feedback loop sustains anti-inflammatory signaling in epithelial cells. bioRxiv, Mar 2026. URL: https://doi.org/10.64898/2026.03.20.711763, doi:10.64898/2026.03.20.711763. This article has 0 citations.

  13. (ferrarese2026anfgf7fgfr2klf4feedback pages 5-7): Luca Ferrarese, Daria Wüst, Liliana Bento Lopes, Ismail Küçükaylak, Sibilla Sander, Joanne Gerber, Jörn Dengjel, and Sabine Werner. An fgf7-fgfr2-klf4 feedback loop sustains anti-inflammatory signaling in epithelial cells. bioRxiv, Mar 2026. URL: https://doi.org/10.64898/2026.03.20.711763, doi:10.64898/2026.03.20.711763. This article has 0 citations.

  14. (ferrarese2026anfgf7fgfr2klf4feedback pages 7-9): Luca Ferrarese, Daria Wüst, Liliana Bento Lopes, Ismail Küçükaylak, Sibilla Sander, Joanne Gerber, Jörn Dengjel, and Sabine Werner. An fgf7-fgfr2-klf4 feedback loop sustains anti-inflammatory signaling in epithelial cells. bioRxiv, Mar 2026. URL: https://doi.org/10.64898/2026.03.20.711763, doi:10.64898/2026.03.20.711763. This article has 0 citations.

  15. (ferrarese2026anfgf7fgfr2klf4feedback pages 40-44): Luca Ferrarese, Daria Wüst, Liliana Bento Lopes, Ismail Küçükaylak, Sibilla Sander, Joanne Gerber, Jörn Dengjel, and Sabine Werner. An fgf7-fgfr2-klf4 feedback loop sustains anti-inflammatory signaling in epithelial cells. bioRxiv, Mar 2026. URL: https://doi.org/10.64898/2026.03.20.711763, doi:10.64898/2026.03.20.711763. This article has 0 citations.

  16. (liu2026fgffamilyin pages 11-12): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

  17. (liu2026fgffamilyin pages 6-8): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

  18. (liu2026fgffamilyin pages 12-13): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

  19. (chen2022rolesofthe pages 8-10): Keyang Chen, Zhiheng Rao, Siyang Dong, Yajing Chen, Xulan Wang, Yongde Luo, Fanghua Gong, and Xiaokun Li. Roles of the fibroblast growth factor signal transduction system in tissue injury repair. Burns & Trauma, Mar 2022. URL: https://doi.org/10.1093/burnst/tkac005, doi:10.1093/burnst/tkac005. This article has 57 citations and is from a peer-reviewed journal.

  20. (chen2022rolesofthe pages 10-11): Keyang Chen, Zhiheng Rao, Siyang Dong, Yajing Chen, Xulan Wang, Yongde Luo, Fanghua Gong, and Xiaokun Li. Roles of the fibroblast growth factor signal transduction system in tissue injury repair. Burns & Trauma, Mar 2022. URL: https://doi.org/10.1093/burnst/tkac005, doi:10.1093/burnst/tkac005. This article has 57 citations and is from a peer-reviewed journal.

  21. (wang2025recentadvancesin pages 6-8): Jun-Chao Wang, Lu-Sheng Wang, Shuang Gao, and Xiaokun Li. Recent advances in the role of fibroblast growth factors in hair follicle growth. Biomolecules, 15:1198, Aug 2025. URL: https://doi.org/10.3390/biom15081198, doi:10.3390/biom15081198. This article has 6 citations.

  22. (wang2025recentadvancesin pages 8-10): Jun-Chao Wang, Lu-Sheng Wang, Shuang Gao, and Xiaokun Li. Recent advances in the role of fibroblast growth factors in hair follicle growth. Biomolecules, 15:1198, Aug 2025. URL: https://doi.org/10.3390/biom15081198, doi:10.3390/biom15081198. This article has 6 citations.

  23. (wang2025recentadvancesin pages 17-18): Jun-Chao Wang, Lu-Sheng Wang, Shuang Gao, and Xiaokun Li. Recent advances in the role of fibroblast growth factors in hair follicle growth. Biomolecules, 15:1198, Aug 2025. URL: https://doi.org/10.3390/biom15081198, doi:10.3390/biom15081198. This article has 6 citations.

  24. (wang2025recentadvancesin pages 15-17): Jun-Chao Wang, Lu-Sheng Wang, Shuang Gao, and Xiaokun Li. Recent advances in the role of fibroblast growth factors in hair follicle growth. Biomolecules, 15:1198, Aug 2025. URL: https://doi.org/10.3390/biom15081198, doi:10.3390/biom15081198. This article has 6 citations.

  25. (chen2022rolesofthe pages 11-12): Keyang Chen, Zhiheng Rao, Siyang Dong, Yajing Chen, Xulan Wang, Yongde Luo, Fanghua Gong, and Xiaokun Li. Roles of the fibroblast growth factor signal transduction system in tissue injury repair. Burns & Trauma, Mar 2022. URL: https://doi.org/10.1093/burnst/tkac005, doi:10.1093/burnst/tkac005. This article has 57 citations and is from a peer-reviewed journal.

  26. (edirisinghe2025pathologyandtherapeutic pages 23-24): Oshadi Edirisinghe, Gaëtane Ternier, and Thallapuranam Krishnaswamy Suresh Kumar. Pathology and therapeutic significance of fibroblast growth factors. Targets, 3:5, Feb 2025. URL: https://doi.org/10.3390/targets3010005, doi:10.3390/targets3010005. This article has 6 citations.

  27. (edirisinghe2025pathologyandtherapeutic pages 38-40): Oshadi Edirisinghe, Gaëtane Ternier, and Thallapuranam Krishnaswamy Suresh Kumar. Pathology and therapeutic significance of fibroblast growth factors. Targets, 3:5, Feb 2025. URL: https://doi.org/10.3390/targets3010005, doi:10.3390/targets3010005. This article has 6 citations.

  28. (edirisinghe2025pathologyandtherapeutic pages 30-31): Oshadi Edirisinghe, Gaëtane Ternier, and Thallapuranam Krishnaswamy Suresh Kumar. Pathology and therapeutic significance of fibroblast growth factors. Targets, 3:5, Feb 2025. URL: https://doi.org/10.3390/targets3010005, doi:10.3390/targets3010005. This article has 6 citations.

  29. (edirisinghe2024decodingfgffgfrsignaling pages 25-27): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

  30. (farooq2021theroleof pages 11-12): Mariya Farooq, Abdul Waheed Khan, Moon Suk Kim, and Sangdun Choi. The role of fibroblast growth factor (fgf) signaling in tissue repair and regeneration. Cells, 10:3242, Nov 2021. URL: https://doi.org/10.3390/cells10113242, doi:10.3390/cells10113242. This article has 446 citations.

  31. (edirisinghe2025pathologyandtherapeutic pages 28-30): Oshadi Edirisinghe, Gaëtane Ternier, and Thallapuranam Krishnaswamy Suresh Kumar. Pathology and therapeutic significance of fibroblast growth factors. Targets, 3:5, Feb 2025. URL: https://doi.org/10.3390/targets3010005, doi:10.3390/targets3010005. This article has 6 citations.

Artifacts

Citations

  1. edirisinghe2024decodingfgffgfrsignaling pages 5-7
  2. farooq2021theroleof pages 2-5
  3. edirisinghe2024decodingfgffgfrsignaling pages 7-8
  4. edirisinghe2024decodingfgffgfrsignaling pages 1-3
  5. ferguson2021fibroblastgrowthfactor pages 5-7
  6. liu2026fgffamilyin pages 3-4
  7. liu2026fgffamilyin pages 11-12
  8. liu2026fgffamilyin pages 12-13
  9. chen2022rolesofthe pages 8-10
  10. chen2022rolesofthe pages 10-11
  11. wang2025recentadvancesin pages 6-8
  12. wang2025recentadvancesin pages 15-17
  13. chen2022rolesofthe pages 11-12
  14. edirisinghe2025pathologyandtherapeutic pages 23-24
  15. edirisinghe2025pathologyandtherapeutic pages 30-31
  16. farooq2021theroleof pages 11-12
  17. edirisinghe2025pathologyandtherapeutic pages 28-30
  18. ferguson2021fibroblastgrowthfactor pages 2-3
  19. ferguson2021fibroblastgrowthfactor pages 8-9
  20. edirisinghe2025pathologyandtherapeutic pages 8-10
  21. ferguson2021fibroblastgrowthfactor pages 3-5
  22. liu2026fgffamilyin pages 6-8
  23. wang2025recentadvancesin pages 8-10
  24. wang2025recentadvancesin pages 17-18
  25. edirisinghe2025pathologyandtherapeutic pages 38-40
  26. edirisinghe2024decodingfgffgfrsignaling pages 25-27
  27. https://doi.org/10.3390/biom14121622,
  28. https://doi.org/10.3390/cells10051201,
  29. https://doi.org/10.3390/cells10113242,
  30. https://doi.org/10.3390/targets3010005,
  31. https://doi.org/10.64898/2026.03.20.711763,
  32. https://doi.org/10.1186/s43556-026-00429-0,
  33. https://doi.org/10.1093/burnst/tkac005,
  34. https://doi.org/10.3390/biom15081198,